ELTP — Elite Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $212.56m
- $214.83m
- $56.63m
- 52
- 60
- 59
- 58
Annual cashflow statement for Elite Pharmaceuticals, fiscal year end - March 31st, USD millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -2.24 | 5.09 | 8.9 | 3.56 | 20.1 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 2.33 | -0.137 | -0.417 | 0.525 | 7.17 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -3.21 | -3.07 | -1.01 | -2.03 | -11.9 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -1.79 | 3.19 | 6.51 | 3.34 | -3.28 |
| Capital Expenditures | -0.035 | -0.33 | -0.499 | -5.74 | -0.81 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0 | 0.067 | 0 | — | — |
| Sale of Fixed Assets | |||||
| Sale of Intangible Assets | |||||
| Cash from Investing Activities | -0.035 | -0.263 | -0.499 | -5.74 | -0.81 |
| Financing Cash Flow Items | — | — | — | — | 0.046 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 0.69 | -0.87 | -0.667 | 1.7 | 3.39 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -1.14 | 2.06 | 5.34 | -0.696 | -0.706 |